CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Rehabilitation exercise protocolWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug3036 turkish physicians Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D020521 Stroke NIH 0.32
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001297 Stroke HPO 0.32

There is one clinical trial.

Clinical Trials

1 Physiotherapy as a Complimentary Treatment in Reducing Viral-Load, Complications, Death, Expedite Discharge and Improve Quality of Life, Exercise Endurance and Capacity in Stroke Survivors With CoViD-19: A Clinical-Controlled Study

Background: Coronavirus (CoViD-19) positive stroke survivors (SSv) with comorbidities faces possibility for mortality. Study reports success of physiotherapy in CoViD-19 positive SSv with multiple comorbidities. Methods: This clinical controlled study involve a minimum of 30 SSv and 30 age and sex-matched non-stroke individuals with multiple comorbidities with CoViD-19 status confirmed using Real-Time Quantitative-Polymerase Chain Reaction. The Cycle Threshold (CT) and nucleic acid content in the test sample (NA) will be recorded from the virology test results. Their exercise endurance, exercise capacities and quality of life will be assessed using 3-minutes' walk test and 3-meters test and Stroke Specific Quality of Life Questionnaire. Measurements will be taken at every three days intervals from admission to discharge from hospital-isolation. They will receive their normal treatments for CoViD-19 in addition to daily Physiotherapy for the SSv delivered through E-Platform. the Zoom and the WhatsApp video platforms will be used for the interactions between the physiotherapists and the participants. A pre-tested exercise protocol for stroke patients developed by the Stroke and Nervous System Disorders research group of the University of Lagos, Nigeria will be used for the E-exercises. The exercise package will be loaded into the phones of the participants at hospital admission. The Physiotherapists will lead in the exercises through video interaction will the participants watches the video programme. Their risks for respiratory complications (RC), ventilation (RV) and death (RD) will be analysed. Data will be analysed using independent t-test, Analysis of Co-Variance, and multivariate retrogression, survival analyses, Friedman Analysis of Variance and MannWithney U test (95% Confident Interval). Anticipated Outcomes: It is anticipated that the outcome of this study will provide evidence for inclusion of Physiotherapy in the acute management of individuals tested positive for CoViD-19 most important for the stroke survivors tested positive for CoViD-19 at acute stage to reduce the odds of developing complications expedite discharge and reduce odd of death.

NCT04471831 Corona Virus Infection Stroke Other: Rehabilitation exercise protocol
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Stroke
HPO:Stroke

Primary Outcomes

Description: The CT value of a reaction is defined as the cycle number when the fluorescence of a PCR product can be detected above the background signal. The CT value is associated with the amount of PCR product in the reaction. The lower the CT value, the more PCR product that is present. It does not have unit of measurement

Measure: Cycle Threshold (CT) values as recorded from the series of the qRT-PCR

Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

Description: This is the inverse of the Cycle Threshold. It does not have unit of measurement.

Measure: Nucleic acid values as calculated from the Cycle Threshold recorded from the series of the qRT-PCR

Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

Description: Perceived life experience by the participants in relation to the present situation. It does not have unit of measurement.

Measure: Quality of Life perception

Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

Description: The maximum amount of physical exertion that a patient can sustain. It will be tested using the 3-metre walk test. This is the time taken to complete a 3-metre distance. The unit of measurement is in seconds

Measure: Exercise capacity

Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

Description: The maximum length a patient can sustain an exercise procedure, It will be tested using the 3-minutes' walk test This is the distance covered within a 3-minute walk. The unit of measurement is in metres

Measure: Exercise endurance

Time: From date of admission until the date of discharge from the isolation ward or date of death, whichever came first, assessed up to 18 months. Length of hospital stay before discharge/death will be documented

Related HPO nodes (Using clinical trials)

HP:0001297: Stroke
Genes 174
TANGO2 JAG1 SMARCAL1 LIMK1 MMUT RFC2 VHL TREX1 PCNT ENG JAK2 TTR CCM2 COX2 COX1 TRNF GTF2I KRAS CPS1 GDF2 SMAD3 TET2 TRNW ABCC6 MFAP5 TGFBR3 APP ELN ADA2 TRNF OTC LMNA LOX FLNA GATA6 CLIP2 ELN XYLT1 APP PNP THPO GNAQ ADA2 SH2B3 TRNC GYS1 F2 SCN5A GATA4 TGFB3 SNAP29 HBB GLA SMAD4 NPPA TRNS2 COL4A1 ACVRL1 TRNK TRNL1 ND1 ND4 TNNT2 KCNQ1 FBN1 COX1 ACVRL1 AGXT COL3A1 TGFBR1 MYPN TGFB2 TRNW APP ALOX5AP PRNP COX3 TRNQ ND5 RFT1 TP53 XYLT2 MYH11 MPL CALR MYBPC3 MECP2 ND6 CST3 CYTB ACTA2 MYD88 ND5 F5 ENG ELN CYTB SMAD4 TRNV SLC2A10 PRKG1 MLXIPL GUCY1A1 HTRA1 TBL2 COX3 MTHFR PRKCH PRKAG2 NR3C1 TREX1 SLC19A2 PIK3C2A APP NR2F2 ZAP70 TGFBR2 WFS1 GLA MYLK APP NOTCH3 TRNS1 COX2 TPP2 COL4A1 KIF20A CBS BAZ1B TRNS2 ANGPTL6 TNXB TRNQ MPL ENG MAT2A JAK2 ZMPSTE24 ASS1 CYP11B1 TET2 SMAD4 MPL TNNI3 ACAD9 ND6 TRNS1 STIM1 HSD11B2 SLC19A2 DYRK1B PMM2 FLNC GTF2IRD1 SON ACTG1 FOXE3 TRNL1 THSD1 NOS3 GUCY1A1 MYH11 ACTB TRNH NAGS HTRA1 PIGA CST3 MYH11 COL3A1 ND1 JAK2 DPM3 CRELD1
Protein Mutations 10
A143T C807T G20210A I843S L33P M235T N215S R112H V34L V66M
SNP 5
rs10033464 rs1906591 rs2106261 rs333 rs6265